Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma

被引：0
|
作者：
Gay, Francesca [1 ]
Hayman, Suzanne [1 ]
Lacy, Martha Q. [1 ]
Buadi, Francis [1 ]
Gertz, Morie A. [1 ]
Kumar, Shaji [1 ]
Dispenzieri, Angela [1 ]
Mikhael, Joseph R. [2 ]
Bergsagel, Leif [2 ]
Dingli, David [1 ]
Reeder, Craig B. [2 ]
Lust, John A. [1 ]
Russel, Stephen [1 ]
Roj, Vivek [3 ]
Zeldenrust, Steven R. [1 ]
Witzig, Thomas E. [1 ]
Fonseca, Rafael [2 ]
Kyle, Robert [1 ]
Greipp, Philip R. [1 ]
Stewart, A. Keith [2 ]
Rajkumar, S. Vincent [1 ]
机构：
[1] Mayo Clin, Coll Med, Div Hematol, Rochester, MN USA
[2] Mayo Clin Scottsdale, Div Hematol Oncol, Coll Med, Scottsdale, AZ USA
[3] Mayo Clin, Coll Med, Div Hematol Oncol, Jacksonville, FL 32224 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1494 / 1495
页数：2
相关论文
共 50 条
  • [31] BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE AS PRIMARY INDUCTION THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA SIGNIFICANTLY DECREASES BONE RESORPTION WHILE SPARING BONE FORMATION AS COMPARED TO THALIDOMIDE-DEXAMETHASONE
    Tosi, P.
    Zamagni, E.
    Tacchetti, P.
    Perrone, G.
    Ceccolini, M.
    Brioli, A.
    Pallotti, M.
    Pantani, L.
    Petrucci, A.
    Baccarani, M.
    Cavo, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 265 - 265
  • [32] Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
    Jimenez-Zepeda, Victor Hugo
    Dominguez-Martinez, Virginia Jeanet
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (03) : 239 - 244
  • [33] Thalidomide plus dexamethasone for newly diagnosed myeloma
    Lindsey, H
    [J]. LANCET ONCOLOGY, 2002, 3 (12): : 711 - 711
  • [34] T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma
    Mark, Tomer M.
    Shah, Manan
    Rodriguez, Melissa
    Quinn, Ryann
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Mignott, Patrice
    Jayabalan, David
    Ely, Scott A.
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    [J]. BLOOD, 2011, 118 (21) : 1267 - 1268
  • [35] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Maclachlan, Kylee H.
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander
    Usmani, Saad Z.
    [J]. BLOOD, 2023, 142
  • [36] Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency
    Tosi, Patrizia
    Zamagni, Elena
    Tacchetti, Paola
    Ceccolini, Michela
    Perrone, Giulia
    Brioli, Annamaria
    Pallotti, Maria Caterina
    Pantani, Lucia
    Petrucci, Alessandro
    Baccarani, Michele
    Cavo, Michele
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) : 1115 - 1121
  • [37] Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
    Dimopoulos, M. A.
    Stewart, A. K.
    Masszi, T.
    Spicka, I.
    Oriol, A.
    Hajek, R.
    Rosinol, L.
    Siegel, D.
    Mihaylov, G. G.
    Goranova-Marinova, V.
    Rajnics, P.
    Suvorov, A.
    Niesvizky, R.
    Jakubowiak, A.
    San-Miguel, J.
    Ludwig, H.
    Ro, S.
    Aggarwal, S.
    Moreau, P.
    Palumbo, A.
    [J]. BLOOD CANCER JOURNAL, 2017, 7 : e554 - e554
  • [38] Phase II Trial of Syncopated Thalidomide, Lenalidomide, and Weekly Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Tufail, Madiha
    Siegel, David S.
    McBride, Laura
    Bilotti, Elizabeth
    Bello, Erica
    Anand, Palka
    Olivo, Karly
    Bendarz, Urszula
    McNeill, Ann
    Vesole, David H.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (03): : 186 - 190
  • [39] BORTEZOMIB PLUS DEXAMETHASONE VERSUS REDUCED-DOSE BORTEZOMIB PLUS THALIDOMIDE-DEXAMETHASONE AS INDUCTION PRIOR TO AUTOLOGOUS TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA
    Harousseau, J. L.
    Avet-Loiseau, H.
    Mary, J.
    Facon, T.
    Attal, M.
    Doyen, C.
    Hulin, C.
    Garderet, L.
    Tiab, M.
    Lepeu, G.
    Araujo, C.
    Caillot, D.
    Petillon, M.
    Mathiot, C.
    Moreau, P.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 451 - 451
  • [40] Bortezomib (velcade(R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)
    Cavo, Michele
    Patriarca, Francesca
    Tacchetti, Paola
    Galli, Monica
    Perrone, Giulia
    Petrucci, Maria Teresa
    Brioli, Annamaria
    Bringhen, Sara
    Pantani, Lucia
    Tosi, Patrizia
    Crippa, Claudia
    Zamagni, Elena
    Di Raimondo, Francesco
    Narni, Franco
    Cellini, Claudia
    Ceecolini, Michela
    Pescosta, Norbert
    Goldaniga, Maria Cecilia
    Montefusco, Vittorio
    Callea, Vincenzo
    De Stefano, Valerio
    Caravita, Tommaso
    Boccadoro, Mario
    Baccarani, Michele
    [J]. BLOOD, 2007, 110 (11) : 30A - 30A
12345